| Q73296338 | A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice |
| Q35180578 | An evidence-based approach to prostate cancer follow-up |
| Q41142697 | Bisphosphonates and the treatment of bone disease in the elderly |
| Q24244161 | Bisphosphonates for advanced prostate cancer |
| Q47248454 | Bisphosphonates for advanced prostate cancer. |
| Q32139406 | Bisphosphonates for the relief of pain secondary to bone metastases. |
| Q35580997 | Bisphosphonates to Prevent Skeletal Complications in Men With Metastatic Prostate Cancer |
| Q36716615 | Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease |
| Q37809860 | Burden of metastatic bone disease from genitourinary malignancies |
| Q43837282 | Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease |
| Q34348296 | Complementary and alternative therapies for advanced prostate cancer |
| Q33800964 | Complications of advanced prostate cancer |
| Q35145701 | Current strategies in the management of hormone refractory prostate cancer |
| Q56562762 | Editorial: Palliative care in oncology: Making quality the endpoint |
| Q74472410 | Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton |
| Q37145394 | Etidronate: what is its place in treatment of primary osteoporosis and other demineralizing diseases today? |
| Q40594555 | Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease |
| Q38785899 | Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project |
| Q30416693 | Hospice and palliative care |
| Q44259274 | Ibandronate in the treatment of prostate cancer associated painful osseous metastases |
| Q36723151 | Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy |
| Q35675197 | Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies |
| Q35145704 | Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment |
| Q44251611 | Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group |
| Q71466228 | Self-assessed sexual function after pelvic irradiation for prostate carcinoma. Comparison with an age-matched control group |
| Q69374619 | Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases |
| Q38917438 | Skeletal complications in cancer patients with bone metastases |
| Q34558618 | Strategies for management of prostate cancer-related bone pain |
| Q77522861 | Systemic treatment for prostate cancer |
| Q36129779 | The management of intractable bone pain: a clinician's perspective |
| Q35081743 | The potential role of bisphosphonates in prostate cancer |
| Q35095379 | The role of bisphosphonates in the management of metastatic prostate cancer. |
| Q36450794 | The role of bisphosphonates in the management of prostate cancer |
| Q45144869 | Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients |
| Q34065811 | Use of bisphosphonates in skeletal metastasis |
| Q34162842 | Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care |
| Q41471544 | Utility of bisphosphonates in treating bone metastases |
| Q38101500 | Zoledronic acid in genitourinary cancer |
| Q81093315 | [Pharmacotherapy of cancer pain. 3. Adjuvant drugs.]. |